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Background: The hepaCAM gene encodes a new immunoglobulin-like cell adhesion molecule, and its expression
is suppressed in a variety of human cancers. Additionally, hepaCAM possesses properties often observed in tumor
suppressor genes. However, the expression and biological function of hepaCAM has not been investigated in
bladder cancer. Therefore we sought to examine hepaCAM expression and the relationship between its structure
and function in human transitional cell carcinoma of bladder (TCCB).
Materials and methods: HepaCAM expression was evaluated in 28 normal and 34 TCCB bladder specimens and 2
TCCB cell lines using semi-quantitative RT-PCR. The wild-type hepaCAM and the extracellular domain-truncated
mutant gene were transfected into the TCCB cell line T24, and the biological properties of both the wild-type gene
and the domain-truncated mutant were then assessed.
Results: HepaCAM expression was down-regulated in 82% (28/34) of TCCB specimens and undetectable in the 2
TCCB cell lines tested. The localization of hepaCAM appeared to be dependent on cell density in T24 cells. In
widely spread cells, hepaCAM accumulated on the perinuclear membrane and the cell surface protrusions, whereas
in confluent cells, hepaCAM was predominantly localized at the sites of cell-cell contacts on the cell membrane.
Functionally, hepaCAM expressed not only increased cell spreading, delayed cell detachment, enhanced wound
healing and increased cell invasion; it also inhibited cell growth (P < 0.01). When the extracellular domain was
deleted, the localization of hepaCAM was significantly altered, and it lost both its adhesive function and its
influence on cell growth.
Conclusions: HepaCAM is involved in cell adhesion and growth control, and its expression is frequently silenced in
TCCB. The extracellular domain of hepaCAM is essential to its physiological and biological functions.
Background
Cell-cell and cell-matrix adhesion is essential for normal
organogenesis and for the maintenance of normal tis-
sues in humans. This adhesion is largely mediated by a
large and complex number of adhesion molecules
expressed on the cell surface [1]. They are generally
classified into four types based on their structural and
functional features: cadherins, selectins, integrins, and
members of the immunoglobulin superfamily (IgSF)
[2-5]. An exciting concept that has recently emerged
from recent cell biological research is that cell adhesion
complexes are not simply static architectural entities
that play a role in cell-cell and cell-matrix adhesion.
Rather, these complexes are dynamic units that play a
critical role in modulating cytoplasmic signaling cas-
cades by capturing and integrating signals from the
extracellular environment [6]. These interactions are
vital for the regulation of cellular adhesion, proliferation,
apoptosis, migration, and differentiation.
Recently, Mei Chung Moh et al. identified a novel
gene in the liver that they called hepaCAM (hepatocyte
cell adhesion molecule); this gene is differentially
expressed in human hepatocellular carcinoma as com-
pared to normal liver tissue [7,8]. hepaCAM is located
on chromosome 11q24, contains 7 exons, and encodes a
novel 416 amino acid protein. The protein possesses a
structure that is typical of Ig-like adhesion molecules,
including two extracellular Ig-like domains, a transmem-
brane segment and a cytoplasmic tail [9,10]. Previous
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frequently completely suppressed in human hepatocellu-
lar carcinoma and significantly suppressed in a variety
of other tumor types including malignancies of the lung,
brain, colon, and blood. When transfected into human
hepatocellular carcinoma HepG2 and breast carcinoma
MCF7 cells, the wild-type hepaCAM not only increases
cell spreading on Matrigel matrices, delays cell detach-
ment, and enhances wound healing, but it also reduces
colony formation and inhibits cell growth. It was
recently found that deletion of the cytoplasmic domain
of hepaCAM did not interfere with dimerization, but
that its presence was necessary for hepaCAM to exert
its normal physiological and biological functions
[7,9,10]. Another study showed that deletion of either
the extracellular or the cytoplasmic domain of hepa-
CAM abolished actin co-precipitation and delayed cell-
ECM adhesion and cell motility [11]. Additionally, it
was recently shown that the extracellular first immuno-
globulin domain of hepaCAM was required for the
binding of the caveolar structural protein caveolin-1
[12]. However, the structural domains necessary for the
normal function of hepaCAM remain uncharacterized in
the renal system.
Therefore, in this study, we sought to investigate the
expression of hepaCAM in TCCB as well as the physio-
logical and biological properties of hepaCAM in the
TCCB cell line T24. We showed that hepaCAM is
expressed in normal bladder tissues but that its expres-
sion is decreased or absent in both the TCCB samples
we included in our study and the TCCB cell lines T24
and BIU-87. When transfected into T24 cells, hepaCAM
not only increases cell spreading on Matrigel matrices,
delays cell detachment, and enhances wound healing,
but it also inhibits cell growth. Interestingly, a hepa-
CAM mutant with truncated extracellular domain no
longer exhibits these biological characteristics in T24,
indicating the importance of the extracellular domain in
the function of hepaCAM in bladder tissue.
Methods
Patient characteristics
All of the tumor samples were obtained from patients
newly diagnosed and treated for TCCB at our depart-
ment between 2005 and June 2007. Clinical information
regarding these patients was retrieved from medical
records. Carcinoma specimens were obtained from 34
patients (28 men and 6 women, age range 38 to 76
years) with primary or recurrent bladder cancer. All of
the tumors were initially diagnosed as bladder carci-
noma before surgery based on clinical examinations
including urinary cytology and cystoscopy. Histological
examination of the tumor tissues after surgery con-
firmed that all patients had transitional cell carcinoma.
According to the guidelines of the International Union
Against Cancer, the histologic grade and stage were
determined as follows: Grade G1 in 16; G2 in 8; and G3
in 10; and Stage Ta-T1 in 10; T2-T4 in 24. Normal
bladder tissue samples were surgically excised from 28
unpaired patients (24 men and 4 women, age range 46
to 69 years) without cancer and were confirmed as nor-
mal by histological examination. Patients with bladder
cancer received standardized treatments and underwent
identical post-treatment surveillance. The institutional
review board approved the study protocol. All patients
provided informed consent for the use of their bladder
specimens.
Cell lines
Two human TCCB cell lines, T24 and BIU-87, were
provided by the Basic Medical Sciences Laboratory of
Chongqing Medicine University and maintained and
grown in RPMI-1640 medium supplemented with 10%
fetal bovine serum, 50 U/mL penicillin, and 50 μg/mL
streptomycin in a 5% carbon-dioxide-containing humidi-
fied incubator at 37°C.
RT-PCR and determination of relative hepaCAM
expression levels
The primers and probes for the hepaCAM gene were
chosen with the assistance of the computer program
Primer Premier 5.0 (PremierBiosoft, USA). We then
conducted a BLASTN search using the GenBank data-
base to confirm the total gene specificity. A forward pri-
mer (5’-TAC TGT AGA TGT GCC CAT TTC G-3)
and reverse primer (5’-CTT CTG GTT TCA GGC GGT
C-3’) were used to generate a hepaCAM fragment of
461 bp from 0.1 μg DNase-treated total RNA. Beta-actin
was used as a control. Semi-quantitative RT-PCR reac-
tions were performed with the Two-step RT-PCR kit
(Takara, Japan) following the manufacturer’sp r o t o c o l .
Polymerase chain reaction (PCR) was carried out using
the primers for the indicated genes under optimized
conditions. Details regarding the PCR conditions and
gene-specific primers are available on request.
The semi-quantitative analysis of the amplified PCR
products was performed using a BIO-RAD imaging
plate (BIO-RAD, USA). All samples were analyzed
simultaneously. The relative amount of each hepaCAM
mRNA was normalized to a beta-actin signal from the
same sample. The results are expressed as the hepa-
CAM/beta-actin ratio, which was defined as the expres-
sion level for the respective hepaCAM gene.
Biological properties of the wild-type and mutant
hepaCAM genes in T24 cells
The plasmids containing wild type hepaCAM and the
mutant hepaCAM with a truncated extracellular domain
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the recombinant plasmids were verified by sequencing.
The complete coding sequences of hepaCAM and its
truncated extracellular domain mutant were generated
by PCR amplification. The cDNAs of wild-type hepa-
CAM (residues 1-416) and mutant hepaCAM (residues
240-416) were cloned into the pEGFP-N2 vector (Clon-
tech, Palo Alto, CA) at the HindIII/BamHI restriction
sites. The constructs were named hepaCAM-GFP and
hepaCAM-mt1-GFP, respectively. When the transfected
T24 cells expressed hepaCAM-GFP or hepaCAM-mt1-
GFP, this could be detected by an anti-GFP antibody,
fluorescence microscopy, or confocal microscopy. Tran-
sient transfections were carried out with Lipofectamine
2000TM (Invitrogen). T24 cells grown on coverslips
were transfected with hepaCAM-GFP, hepaCAM-mt1-
GFP, and pEGFP-N2 vector. Then, these cells were
selected using 400 μg/ml of G418 for 4 weeks, and sub-
sequently cloned.
Total protein (50 μg) from the cells was resolved by
SDS-PAGE, transblotted onto a membrane (Santa Cruz,
CA), and detected using a rabbit anti-GFP monoclonal
antibody (Santa Cruz, CA). The membranes were then
stripped with a mouse anti-rabbit antibody to assess
loading quantity.
Cells were seeded in plates coated with 40 μgo f
Matrigel basement membrane matrix (Collaborative
Research) and incubated under standard conditions. Cell
morphology was observed by microscopy. Unspread
cells were defined as round cells, while spread cells were
defined as cells with extended cellular processes. The
percentage of cells demonstrating a spread morphology
was quantified in 10 randomly selected fields (>60 cells/
field).
A confluent monolayer of cells was detached using
1 mM EDTA in PBS at 37°C. Cell detachment was
evaluated under the inverted microscope after 5 minutes
and 15 minutes of incubation. Concurrently, the disso-
ciated cells were harvested and counted in 10 randomly
selected fields.
Cells were seeded onto 35-mm culture plates at high
density and allowed to form monolayers overnight.
Then, the cells were wounded with a sterile 200-μl plas-
tic micropipette tip. The wound was examined micro-
scopically at 12 and 24 hours. The changes in diameter
(D) of each wound were measured by microscopy and
computed into a ratio (D24/Dinitial × 100%) reflecting
the degree of wound closure that had occurred.
Cell invasion was assessed using transwell chambers
with 8-μg pore-size membranes coated with Matrigel
(Collaborative Research) that were placed in 24-well
plates. Cells (5 × 10
4) were loaded into the upper seg-
ment of the chambers and allowed to invade through
the membrane for 24 h. In the upper segment of the
chambers is the 5% fetal bovine serum, in the under
chambers is the 10% fetal bovine serum, The cells will
growth form low level serum to higher level serum. The
invasion cells were harvested by trypsinizing the lower
surface of the membrane and were collected. Non-
migrated cells were then removed. The invasion cells
were harvested by trypsinizing the lower surface of the
membrane and were collected and seeded into a new
24-well plate, 500 μl 0.1%gentian violet was add into 24-
well plate, place the membrane into it, in 37°C take out
the membrane after 30 min, wash the membrane with
PBS. The invasion activity was then quantified by blind
counting of the invasion cells in 10 randomly selected
microscopic fields (>40 cells/field).
The growth rate of T24 cell lines were monitored for
seven days. Cells were seeded in triplicate and cultured
under standard conditions. Every 24 h, cell viability was
determined by MTT assay. The growth rate of each cell
line was presented as fold of increase in cell viability as
compared to the respective baseline value.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences version 13.0, for Windows.
Nonparametric ANOVA was performed to compare the
difference among more than two parameters. Fisher’s
exact test was used to assess the correlation between
two parameters. Statistical significance in this study was
set at P < 0.05. All reported P values are two-sided.
Results
Expression of hepaCAM mRNA and its correlation with
clinical and patholagical features of bladder cancer
Semi-quantitative RT-PCR revealed that hepaCAM was
expressed at a similar level in all of the 28 normal blad-
der tissue specimens that we tested. We also examined
hepaCAM mRNA levels in 34 TCCB specimens. The
results showed that hepaCAM expression was reduced
in 82% (28/34) of TCCB tissues. The expression of
hepaCAM was not detectable in eight TCCB specimens
and in the TCCB cell lines we tested. These data
implied an association between the loss of hepaCAM
expression and the presence of TCCB. However, no sta-
tistically significant difference could be detected when
we examined possible correlations between hepaCAM
expression levels and various clinicopathological para-
meters [Fig. 1A, B. Table 1].
The biological properties of hepaCAM in the T24 cell line
Western blot analysis (using a rabbit anti-GFP monoclo-
nal antibody for detection) revealed the results of the
transfections we performed. In the T24 cells transfected
with pEGFP-N2, a specific 27-kDa band was observed.
In the T24 cells transfected with hepaCAM or
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were observed.
To determine the localization of hepaCAM, T24 cells
were transiently transfected with either hepaCAM-GFP
or hepaCAM-mt1-GFP. The GFP vector alone served as
a control. As visualized by confocal microscopy, in well-
spread cells, hepaCAM was localized on the pronuclear
membrane, in the cytoplasm, and at the tip of cell sur-
face protrusions that were about to make contact with
adjacent cell surfaces. However, in confluent cells, hepa-
CAM was found to be predominantly accumulated at
the sites of cell-cell contacts on the cell membrane. In
the T24 cells, hepaCAM-mt1 was also predominantly
localized on the perinuclear membrane in the well-
spread cells, but was in the confluent cells, it was non-
specifically localized. These results revealed a difference
in the subcellular localization of hepaCAM and
hepaCAM-mutant in T24 cells, implying that the
extracellular domain may participate in the subcellular
localization of hepaCAM [Fig. 2].
We evaluated the adhesive effects of hepaCAM and its
extracellular domain truncation mutant on T24 cells
using cell adhesion and detachment assays. Our data
showed that on Matrigel, T24/hepaCAM cells spread
the fastest, followed by T24/hepaCAM-mt1 cells, with
the T24/pEGFP-N2 cells showing the slowest rate of
spread. A total of 57.4% and 94.2% of the T24/hepa-
CAM cells exhibited a well-spread morphology on
Matrigel after 30 minutes and 2 hours of incubation,
respectively. In contrast, only 7.3% and 19.1% of the
T24/hepaCAM-mt1 cells and 7.3% and 21.9% of T24/
pEGFP-N2 cells were found to be well-spread at the
same respective times (P < 0.01). In the cell detachment
assay, T24/hepaCAM cells detached 7.0 times and 10.4
times slower than T24/pEGFP-N2 cells at 5 minutes
and 15 minutes, respectively. On the other hand, the
detachment rate of T24/hepaCAM-mt1 cells (52.7% and
97.4%) was not statistically different than that of
the control cells (T24/pEGFP-N2) [51.5% and 97.6%;
(P > 0.05)].
Cell motility mediated by hepaCAM and its extracellu-
lar domain truncation mutant was assessed by wound
healing and Matrigel invasion assays. As revealed by the
wound healing assay [Fig. 3], after 12 hours of incuba-
tion, 50.9% of the scratched area was filled by T24/hepa-
CAM cells, in contrast to 19.0% by T24/hepaCAM-mt1
cells and 21.7% by T24/pEGFP-N2 cells (P < 0.01). After
24 h of incubation, 96.6% of the scratched area was
Figure 1 The expression of hepaCAM gene as determined by semi-quantitative RT-PCR. Products were analyzed on a 1.5% agarose gel.
The 461-bp band is the wild-type hepaCAM gene. Line 1 is the marker. Lines 2 to 5 exhibit the expression of hepaCAM gene in normal bladder
tissue specimens, TCCB specimens, T24 cells, and BIU-87 cells(A). Quantified expression levels of hepaCAM normalized to b-actin expression
levels. Groups 1 to 4 exhibit hepaCAM gene expression levels in normal bladder tissue specimens, TCCB specimens, T24 cells, and BIU-87 cells(B).
Table 1 Correlation between hepaCAM suppression and








Total number 28 6 82
Sex
Male 22 6 79 NS
Female 6 0 100 NS
Histologic grade
Ta-T1 4 6 40
T2-T4 24 0 100
Histologic stage
G1 14 2 88 NS
G2 7 1 88 NS
G3 7 3 70 NS
occurrence
Primary 16 4 80 NS
Recurrence 12 2 86 NS
KEY: NS = not significant; * Mann-Whitney U test; P < 0.05 was considered
statistically significant
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and its extracellular domain truncation mutant were localized on the perinuclear membrane and at the tip of cell surface protrusions. [B, C
(white arrows indicate the localization of wild-type hepaCAM and its mutant), A is the control group]. In confluent cells, hepaCAM
predominantly accumulated at the sites of cell-cell contacts on the cell membrane (E). However, in confluent cells, hepaCAM-mt1 did not
accumulate at the sites of cell-cell contact, but instead localized on the cell membrane non-specifically (F, white arrows indicate localization of
hepaCAM-mt1). D is the control group. 1000× magnification.
Figure 3 Wound healing assay. Wounds were made with a pipette tip on confluent T24/pEGFP-N2 (left panel), T24/hepaCAM (middle panel),
and T24/hepaCAM-mt1 (right panel) cells and allowed to heal for 12 and 24 h. 100× magnification(A). The diameters of wounds were measured
on the microscopic photos at 0 h, 12 h, and 24 h after the wound was induced. Changes in wound diameter were computed into percentages
(means ± SD) to represent wound closure. P < 0.01 as assessed by ANOVA(B).
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mt1 cells, and 49.8% by T24/pEGFP-N2 cells (P < 0.01).
In addition, the Matrigel invasion assays showed that
T24/hepaCAM cells had a higher degree of motility
than both T24/hepaCAM-mt1 and the control T24/
pEGFP-N2 cells, The invasion ability of T24/hepaCAM
group(102.30 ± 16.06 cells/field) is higher than the T24/
hepaCAM-mt1 group and control T24/pEGFP-N2
group (P < 0.05), T24/hepaCAM-mt1 group (43.20 ±
10.45 cells/field)and control T24/pEGFP-N2 group
(41.00 ± 9.94 cells/field)is no statistics difference
(P > 0.05). It was noteworthy that both the migration
and invasion capacities of the cells expressing the hepa-
C A Mm u t a n tw e r ec o m p a r a b l et ot h a to ft h ec o n t r o l
cells, indicating that the extracellular domain was essen-
tial for hepaCAM-mediated cell motility and invasion.
To examine the involvement of hepaCAM and its
mutant in the regulation of cell growth, the cell growth
rate was determined in the stable T24 cell clones. The
results showed that the cell growth rate was reduced
about 5-fold in the T24/hepaCAM cells as compared to
the T24/pEGFP-N2 cells (P < 0.01). The growth rate of
T24/hepaCAM-mt1 cells was not significantly different
than that of T24/pEGFP-N2 cells [Fig. 4].
Discussion
HepaCAM was recently demonstrated to be differen-
tially expressed in human hepatocellular carcinoma
[13,14]. Studies have shown that the expression of hepa-
CAM is frequently lost in human hepatocellular carci-
noma and processed a tumor suppressor gene [7,15,16].
However, hepaCAM has not been previously investi-
gated in TCCB. It is well known that the occurrence
and development of human TCCB demonstrates many
similarities to that of HCC. Our hypothesis is that hepa-
CAM may play similar roles in TCCB as in HCC. To
test our hypothesis, we examined the expression of 28
normal bladder tissue specimens, 34 TCCB specimens,
and 2 TCCB cell lines, T24 and BIU-87. The results
showed that the level of expression of hepaCAM in all
of 14 normal bladder tissue specimens was similar, but
that it was decreased in 85% (28/34) of TCCB speci-
mens. Moreover, the expression of hepaCAM was
absent in 26% (8/34) of TCCB specimens and both
TCCB cell lines.
To further evaluate whether or not hepaCAM pos-
sessed any functional roles in the bladder, we assessed
the physiological and biological characteristics of hepa-
CAM in the TCCB cell line T24. Investigations were
carried out to reveal the relationship between the struc-
ture and function of hepaCAM, especially with respect
to the extracellular domain in the bladder. We con-
structed two eukaryotic expression vectors containing
either the wild-type or the extracellular domain-trun-
cated mutant of hepaCAM. The subcellular localization
of hepaCAM appears to depend on cell density in T24
cells. When transfected into T24 cells, hepaCAM is
localized on the perinuclear membrane, in the cyto-
plasm, and at the tip of cell surface protrusions that are
about to make contact with adjacent cell surfaces in
well-spread cells, whereas in confluent cells, hepaCAM
is found to be predominantly accumulated at the sites of
cell-cell contacts on the cell membrane. This finding is
similar to that reported in HepG2 cells, an HCC cell
line. Through cell adhesion and motility assays, we have
observed that hepaCAM increases cell spreading on
Matrigel, delays cell detachment, enhances wound heal-
ing and increases cell invasiveness. The reason that
Figure 4 Inhibition of cell growth by hepaCAM. The growth rate T24/hepaCAM and T24/hepaCAM-mt1 with T24/pEGFP-N2 cells measured
over a seven day period by MTT assay. Data represent means ± SD. P < 0.01 as assessed by ANOVA.
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fact that it increases cell invasiveness is due to the fact
that hepaCAM increases the spreading of T24 cells on
Matrigel, allowing cells to traverse the transwell cham-
bers more easily than the cells that do not express
hepaCAM.
In the cell growth control experiment, the growth rate
of T24/hepaCAM was reduced about 5-fold as com-
pared to T24/pEGFP-N2 cells (P < 0.05). The growth
rate of T24/hepaCAM-mt1 cells did not differ signifi-
cantly from that of T24/pEGFP-N2 cells. This result
indicates that hepaCAM can inhibit the growth of T24
cells much like it does in HepG2 cells. The growth inhi-
bitory effect that hepaCAM has on T24 cells further
supports the hypothesis that hepaCAM may act a tumor
suppressor in the bladder. Furthermore, when the extra-
cellular domain of hepaCAM was deleted, the cell sur-
face localization and the functions of hepaCAM were
drastically altered. Cell-matrix adhesion, cell motility,
and cell growth inhibition were notably weakened in the
hepaCAM extracellular domain truncation mutants
compared to wild-type hepaCAM. Taken together, these
findings suggest that the extracellular domain of hepa-
CAM is essential to the role hepaCAM plays in cell-
matrix interaction and cell motility.
Conclusions
In conclusion, we found that hepaCAM is frequently
suppressed in TCCB, the most common bladder malig-
nancy in humans. We have also shown that hepaCAM
is capable of inhibiting cell growth. These findings
strongly support the hypothesis that hepaCAM may act
as a tumor suppressor gene in the bladder. In addition,
hepaCAM is involved in modulating cell-matrix interac-
tions, and the extracellular domain of hepaCAM is
essential to its biological and physiological functions.
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